Free HPV DNA screening in Navotas shows how diagnostics partnerships can strengthen preventive care

As cervical cancer remains a top threat to Filipinas, a citywide diagnostics partnership in Navotas proves that early detection is a smart economic investment.

There is now a free, citywide HPV DNA screening program available in Navotas, offering women access to preventive and early-detection care without cost. The initiative, launched by the city government in partnership with Roche Diagnostics Philippines, places advanced diagnostics directly inside a local public health system—an approach that has implications beyond healthcare delivery.

HPV, or Human Papilloma Virus, is the leading cause of cervical cancer, which remains the second most common cancer among Filipino women aged 15 to 44. Yet only about 1% of Filipinas have undergone HPV testing, largely because screening is often inaccessible, unaffordable, or poorly integrated into routine care. The result is late diagnosis, higher treatment costs, and longer disruptions to work and family life.

HPV is common and often shows no symptoms, which is why many women do not realize they carry the virus until the disease has already progressed. Without screening, infection can quietly develop into cervical cancer over time, turning what could have been a preventable condition into a life-threatening diagnosis. From an economic standpoint, late-stage illness drives higher medical spending, prolonged hospital use, and income loss—costs that are absorbed not just by households but by local health systems.

Removing structural barriers through innovation

The Navotas program is designed to address these gaps by removing structural barriers. Cost, distance, and lack of information remain the main reasons women delay testing. HPV DNA screening directly detects high-risk strains early, when treatment is simpler, less invasive, and far less disruptive. Early detection also translates to fewer hospital visits, lower long-term medical expenses, and reduced productivity losses, outcomes that matter in densely populated urban communities.

Operationally, the program is anchored by Navotas’ newly opened Molecular Laboratory, equipped with fully automated diagnostic technology aligned with international standards. Unlike Pap smears or VIA screening, HPV DNA testing identifies the virus itself, allowing health workers to intervene earlier and more precisely. The inclusion of self-collection options further lowers participation barriers and improves screening uptake.

Women who test positive are linked directly to follow-up care and treatment through local facilities, creating a clearer, more efficient pathway from diagnosis to intervention. This integration is critical in public systems where fragmented care often results in drop-offs after testing.

“Through citywide HPV DNA testing, Navotas provides women with earlier diagnosis and ensures access to treatment and support, especially in areas beyond the reach of Pap smear and VIA screening,” said Dr. Manuel Mapue II, Development Officer V of the Department of Health Metro Manila Center for Health Development.

The business case for prevention

For Roche Diagnostics Philippines, the partnership illustrates how private-sector diagnostics can be embedded into local government health programs, not as standalone technology, but as part of a broader prevention strategy. Beyond HPV, the same high-throughput systems can support testing for other diseases, allowing cities to maximize infrastructure investments over time.

From a business and policy perspective, the Navotas program highlights a scalable model: pairing local government reach with private-sector diagnostics to shift healthcare spending upstream. Preventive screening may not generate headlines, but it reduces downstream costs, stabilizes public health budgets, and keeps more people economically active. In a system long defined by late intervention, this approach shows what changes when prevention is treated as an investment rather than an afterthought. 

 

 

Through citywide HPV DNA testing, Navotas provides women with earlier diagnosis and ensures access to treatment and support, especially in areas beyond the reach of Pap smear and VIA screening.

Dr. Manuel Mapue II

 

 

READ: